Invasives Zervixkarzinom (pT2b-pT4a)

Hawighorst, H.; Pg, Knapstein; Weikel, W.; Mv, Knopp; Schaeffer, U; Essig, Marco; Brix, G; Zuna, I.; Schönberg, Stefan O.; G, van Kaick

doi:10.1007/s001170050185

Cited by 13 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the vast majority of the cases, a good correlation with immunohistological assessment of tumor angiogenesis was observed [114]. In some situations CED-MRI analysis was a better predictor of disease outcome than histological evaluation of angiogenesis [115] or of circulating VEGF levels [116]. CED-CT is routinely used to measure cerebral blood flow, blood volume, mean transit time and vascular permeability in patients after ischemic brain lesions [117].…”

Section: Imaging-based Techniquesmentioning

confidence: 98%

Inhibition of Angiogenesis by Non-Steroidal Anti-Inflammatory Drugs: From the Bench to the Bedside and Back

Monnier¹,

Zarić²,

Rüegg³

2005

CDTIA

View full text Add to dashboard Cite

The formation of new blood vessels, a process globally referred to as angiogenesis, occurs in a number of pathological conditions, such as cancer and chronic inflammation. Recent findings indicate that cyclooxygenase-2 (COX-2), the inducible form of the cyclooxygenase (COX) isoenzymes, acts as a potent inducer of angiogenesis. Non-steroidal anti-inflammatory drugs (NSAIDs) are classical inhibitors of COX enzymes, which are widely prescribed for the treatment of inflammation, pain and fever. Selective COX-2 inhibitors (COXIBs) have been subsequently developed with the purpose to improve the safety profile of this class of therapeutics. More recently, substantial preclinical evidence demonstrated that NSAIDS and COXIBs have anti-angiogenic properties. This newly recognized activity opens the possibility of using these drugs for the treatment of angiogenesis-dependent diseases. In this article we review the most recent advances in understanding the mechanisms by which NSAIDs and COXIBs suppress angiogenesis, and we discuss their potential clinical use as anti-angiogenic drugs.

show abstract

Section: Imaging-based Techniquesmentioning

confidence: 98%

Inhibition of Angiogenesis by Non-Steroidal Anti-Inflammatory Drugs: From the Bench to the Bedside and Back

Monnier¹,

Zarić²,

Rüegg³

2005

CDTIA

View full text Add to dashboard Cite

show abstract

“…Use of a HTR sequence provides detailed information regarding the initial part of the time intensity curve including MSI, THR and EA. These semi-quantitative parameters are not only correlated with the number of microvessels in breast cancers (positive correlation with immunohistochemical CD31) (23,24) but also reflect parietal immaturity (20). We chose to use a 7.7 sec temporal resolution for our HTR-DCE sequence based on preliminary studies where the sensitivity of the dynamic sequence with a higher temporal resolution was decreased because of low spatial resolution (8).…”

Section: Oldrini Et Al Demonstrated That the Visibility Of Breast Lesions On Tricks Acquisitionmentioning

confidence: 99%

Abbreviated breast MRI combining FAST protocol and high temporal resolution (HTR) dynamic contrast enhanced (DCE) sequence

Milon

Perre

Poujol

et al. 2019

European Journal of Radiology

View full text Add to dashboard Cite

“…Thus, it has been necessary to develop noninvasive surrogate markers of therapeutic response and efficacy measures for clinical trials involving antiangiogenic drugs [3,4]. Dynamic contrastenhanced magnetic resonance imaging (DCE-MRI) has emerged as a powerful noninvasive tool for serially assessing vascular dynamics within tumor tissue using parameters deduced from pharmacokinetic modeling [5][6][7][8][9][10][11]. This method exploits the abnormal hierarchical branching patterns and increased permeability of tumor vasculature [12 -14] through the influx, interstitial space extravasation, and washout of nonspecific lowmolecular-weight contrast agents.…”

Section: Introductionmentioning

confidence: 99%

Microarray Gene Expression Analysis of Murine Tumor Heterogeneity Defined by Dynamic Contrast-Enhanced MRI

Costouros¹,

Lorang²,

Zhang

et al. 2002

Mol Imaging

View full text Add to dashboard Cite

Current methods of studying angiogenesis are limited in their ability to serially evaluate in vivo function throughout a target tissue. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and pharmacokinetic modeling provide a useful method for evaluating tissue vasculature based on contrast accumulation and washout. While it is often assumed that areas of high contrast enhancement and washout comprise areas of increased angiogenesis and tumor activity, the actual molecular pathways that are active in such areas are poorly understood. Using DCE-MRI in a murine subcutaneous tumor model, we were able to perform pharmacokinetic functional analysis of a tumor, coregistration of MRI images with histological cross-sections, immunohistochemistry, laser capture microdissection, and genetic profiling of tumor heterogeneity based on pharmacokinetic parameters. Using imaging as a template for biologic investigation, we have not found evidence of increased expression of proangiogenic modulators at the transcriptional level in either distinct pharmacokinetic region. Furthermore, these regions show no difference on histology and CD31 immunohistochemistry. However, the expression of ribosomal proteins was greatly increased in high enhancement and washout regions, implying increased protein translation and consequent increased cellular activity. Together, these findings point to the potential importance of posttranscriptional regulation in angiogenesis and the need for the development of angiogenesis-specific contrast agents to evaluate in vivo angiogenesis at a molecular level.

show abstract

Invasives Zervixkarzinom (pT2b-pT4a)

Cited by 13 publications

References 0 publications

Inhibition of Angiogenesis by Non-Steroidal Anti-Inflammatory Drugs: From the Bench to the Bedside and Back

Inhibition of Angiogenesis by Non-Steroidal Anti-Inflammatory Drugs: From the Bench to the Bedside and Back

Abbreviated breast MRI combining FAST protocol and high temporal resolution (HTR) dynamic contrast enhanced (DCE) sequence

Microarray Gene Expression Analysis of Murine Tumor Heterogeneity Defined by Dynamic Contrast-Enhanced MRI

Contact Info

Product

Resources

About